Seven Fleet Capital Management LP Makes New $976,000 Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Seven Fleet Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 102,493 shares of the biotechnology company’s stock, valued at approximately $976,000.

Several other large investors have also recently bought and sold shares of the business. NewEdge Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 4.6% in the 1st quarter. NewEdge Advisors LLC now owns 52,326 shares of the biotechnology company’s stock valued at $498,000 after acquiring an additional 2,285 shares during the last quarter. Perceptive Advisors LLC raised its position in shares of BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after acquiring an additional 4,271,504 shares in the last quarter. Bank of America Corp DE lifted its stake in BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after purchasing an additional 3,556,208 shares during the last quarter. Janus Henderson Group PLC lifted its stake in BioCryst Pharmaceuticals by 20.3% during the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after purchasing an additional 1,504,120 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 133.3% in the first quarter. ADAR1 Capital Management LLC now owns 105,000 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 60,000 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 2.8%

NASDAQ BCRX opened at $8.98 on Friday. The firm has a market cap of $2.28 billion, a P/E ratio of -5.04 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.22. The business’s 50-day moving average price is $9.30 and its 200 day moving average price is $8.63.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same period in the prior year, the company earned $0.20 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Citizens Jmp upped their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.